Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Background: Hyperkalemia increases risk of cardiac arrhythmias and death and limits the
use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor …

Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has
significant protective benefits for the heart and kidney. We aimed to see whether this agent …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Sodium-Glucose Cotransporter 2 inhibitors (SGLT2i), or gliflozins, are a group of antidiabetic
drugs that have shown improvement in renal and cardiovascular outcomes in patients with …

Abstract Sodium–glucose cotransporter (SGLT) 2 inhibitors have been demonstrated to
reduce cardiovascular events, particularly heart failure, in cardiovascular outcome trials …